Impact of chromium dinicocysteinate supplementation on inflammation, oxidative stress, and insulin resistance in type 2 diabetic subjects: an exploratory analysis of a randomized, double-blind, placebo-controlled study.
BACKGROUND
Chromium dinicocysteinate (CDNC) is a unique chromium complex consisting of chromium, niacin, and L-cysteine. Previous preclinical and clinical studies support the safety and efficacy of CDNC in modulating oxidative stress, vascular inflammation, and glycemia in type 2 diabetes.


OBJECTIVE
Herein, we report the results of several exploratory analyses conducted on type 2 diabetic subjects who previously participated in a 3-month randomized, double-blind, placebo-controlled trial and were treated with only metformin as standard diabetic care in addition to receiving the test supplementations.


METHODS
Results from 43 metformin users, who were randomly assigned to receive either placebo (P, n=13), chromium picolinate (CP, 400 µg elemental Cr(3+)/day, n=12), or CDNC (400 µg elemental Cr(3+)/day, n=18), were analyzed for blood markers of vascular inflammation, insulin resistance, and oxidative stress at baseline and at 3 months of supplementation.


RESULTS
A statistically significant decrease in insulin resistance in the CDNC-supplemented cohort compared to placebo (p=0.01) was observed at 3 months. The CDNC group also demonstrated a significant reduction in insulin levels (p=0.03), protein carbonyl (p=0.02), and in TNF-α (p=0.03) compared to the placebo group. The CP group only showed a significant reduction in protein carbonyl levels (p=0.03) versus placebo.


CONCLUSIONS
When controlling for diabetes medication, CDNC supplementation showed beneficial effects on blood markers of vascular inflammation, insulin resistance, and oxidative stress compared to placebo. The findings suggest that CDNC supplementation has potential as an adjunct therapy for individuals with type 2 diabetes.
InterHealth Nutraceuticals, Benicia, CA, USA; zsaiyed@interhealthusa.com.
Zainulabedin M
ZM
Saiyed
InterHealth Nutraceuticals, Benicia, CA, USA.
James P
JP
Lugo
chromium dinicocysteinate; diabetes; insulin resistance; oxidative stress; vascular inflammation
Antioxid Redox Signal. 2007 Jul;9(7):955-69
17508917
Cytokine. 2006 May;34(3-4):219-23
16822679
Diabetes Care. 2004 Nov;27(11):2741-51
15505017
Am J Epidemiol. 2005 Jul 15;162(2):157-64
15972934
Mol Nutr Food Res. 2012 Aug;56(8):1333-41
22674882
Horm Metab Res. 2007 Oct;39(10):743-51
17952838
Antioxid Redox Signal. 2011 Oct 1;15(7):1911-26
21126197
Proc Nutr Soc. 2004 Feb;63(1):41-7
15070438
Diabetes Care. 2009 Jan;32(1):193-203
18945920
Circulation. 2005 May 17;111(19):2446-53
15867184
Diabetes Care. 2007 Aug;30(8):2154-63
17519436
Diabetes Care. 2004 Sep;27(9):2211-6
15333486
J Am Coll Nutr. 1998 Dec;17(6):548-55
9853533
Diabetes. 1997 Nov;46(11):1786-91
9356027
Mol Nutr Food Res. 2010 Sep;54(9):1371-80
20306473
Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):1040-52
15998259